CVS, UnitedHealth Seek FTC Chair's Removal from Insulin Pricing Suit

The companies argue that FTC Chair Lina Khan and two commissioners have shown bias against pharmacy benefit managers.

CVS Health, UnitedHealth Group, and Cigna have requested that FTC Chair Lina Khan and two commissioners be disqualified from a lawsuit over insulin pricing.
The companies claim that Khan, along with Commissioners Rebecca Kelly Slaughter and Alvaro Bedoya, have displayed bias against pharmacy benefit managers (PBMs).
The lawsuit accuses the PBMs of inflating insulin prices and prioritizing drugs with higher rebates, which allegedly increases costs for patients.
CVS and UnitedHealth argue that public statements made by the commissioners demonstrate prejudgment and a lack of impartiality in the case.
Previous attempts by Amazon and Meta to have Khan removed from FTC cases due to alleged bias have been unsuccessful.